Nyrada Inc. Appendix 4D Half-year report
Half yearly Results and Appendix 4D
Nyrada Half Year FY2025 Results
Highlights: •Development of lead drug candidate NYR-BI03 continues: -Preclinical efficacy study demonstrated 86% cardioprotective effect following myocardial ischemia-reperfusion injury. -Phase… Read more
Nyrada Quarterly Activities Report & Appendix 4C
Highlights: •Development of lead drug candidate NYR-BI03 continues to advance: -Preclinical efficacy study demonstrated 86% cardioprotective effect following myocardial ischemia… Read more
Nyrada’s Lead Drug Candidate Demonstrates Significant Cardioprotection
On Tuesday morning, Nyrada Inc. (ASX: NYR) released a significant announcement about a potential new indication for its lead drug… Read more
Nyrada GLP Studies Update
Highlights: •Two key safety studies have provided data to support safety and tolerability of Nyrada’s lead Brain Injury drug candidate… Read more
Nyrada Quarterly Activities Report & Appendix 4C
Nyrada remains on track for 2QFY2025 commencement of first in-human Phase I clinical trial for its Brain Injury drug candidate… Read more
Nyrada Inc – Nyrada Commences Walter Reed Traumatic Brain Injury Study
Highlights: •Walter Reed Army Institute of Research study of NYR-BI03 in traumatic brain injury has commenced and is expected to… Read more
Nyrada Inc – Investor Presentation
April 2024 Investor Presentation
Nyrada Inc – Nyrada Quarterly Activities Report & Appendix 4C
Highlights: • Lead Brain Injury Program drug candidate NYR-BI03 demonstrated strong efficacy: – rescued average 42% of the brain injury… Read more